Around the time the human genome was sequenced, Adam Margolin, PhD, was a student at The Wharton School who spent two summers interning at Bear Stearns. After the second summer, Margolin refocused his data analysis training to work with DNA sequencing data.
“I thought that the same types of approaches that I was being trained on, and could apply to analyzing hedge-fund data, or high-yield bond data, could be applied in a much more interesting, challenging, and meaningful way to analyzing data from cancer patients,” Margolin told Clinical OMICs. “Rather than try to predict the future appreciation of a bond, I could use the same types of approaches to try to predict the future severity of a cancer that can be used to gain insights that can help patients.”
Margolin, a computational biologist, now pursues insights into cancer and other diseases at Icahn School of Medicine at Mount Sinai, which recruited him from Oregon Health & Science University. At Mount Sinai, he leads what is now the Icahn Institute for Data Science and Genomic Technology, formerly the Icahn Institute for Genomics and Multiscale Biology.
The renaming is part of a $200 million commitment by Mount Sinai to accelerate precision medicine by integrating large-scale data analysis with advanced genomic technologies.
“There’s an institutional commitment to really push the boundary on how we leverage large-scale datasets that will be emerging from studies all around the world, coupled with development of advanced genomic technologies for testing therapies, and use that as the basis of how we discover new breakthroughs going forward,” said Margolin, professor and chair of the Department of Genetics and Genomic Sciences and senior associate dean of precision medicine.
Click here to access the rest of this article.